Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (23)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by BLADÉ, J.
Right arrow Articles by ESTAPÉ, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BLADÉ, J.
Right arrow Articles by ESTAPÉ, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 Oxford University Press

research-article

Treatment of Multiple Myeloma in Elderly People: Long-term Results in 178 Patients

JOAN BLADÉ, MONTSERRAT MUÑOZ, MONTSERRAT FONTANILLAS, JESÚS SAN MIGUEL, ANTONIO ALCALÁ, JUAN MALDONADO, CARLES BESSES, MARÍA JESÚS MORO, JAVIER GARCÍA-CONDE, CIRIL ROZMAN, EMILI MONTSERRAT and JORDI ESTAPÉ

Hematology Unit, Hospital Clinic Villarroel 170.08036 Barcelona, Spain

The purposes of the present study have been to analyse the presenting features, response to therapy and survival of myeloma patients aged 70 years or more, in comparison to younger patients. From January 1985 to December 1989, 487 patients with multiple myeloma (MM) were randomized to receive melphalan and prednisone (MP) versus alternating cycles of vincristine, cyclophosphamide, melphalan, and prednisone (VCMP) and vincristine, BCNU, adriamycin, and prednisone (VBAP). The subset of 178 patients who were 70 or more years is the subject of this study, whereas the 309 patients younger than 70 years were used as a control group. The presenting features and response to chemotherapy of older patients were no different to those of the younger population. However, the survival of elderly patients was significantly shorter (median 23.4 vs. 33.5 months, p < 0.001). The overall response rate to MP in older patients was 50% (28% objective plus 22% partial response) compared with 61% (44% objective plus 17% partial response) to combination chemotherapy (p = not significant). Myelosuppression was moderate in both arms, although MP produced a higher degree of thrombocytopenia. There were no significant differences in survival between patients given MP versus VCMP/ VBAP (median, 20 vs. 27 months, p = 0.2). Response to treatment was associated with a significantly longer survival. Older patients with symptomatic myeloma tolerate chemotherapy and should be offered treatment.

Keywords: Multiple myeloma, Elderly people, Prognosis, Chemotherapy

Received February 23, 1996;
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
C. Hulin, T. Facon, P. Rodon, B. Pegourie, L. Benboubker, C. Doyen, M. Dib, G. Guillerm, B. Salles, J.-P. Eschard, et al.
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
J. Clin. Oncol., August 1, 2009; 27(22): 3664 - 3670.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
M.-V. Mateos, J. M. Hernandez, M. T. Hernandez, N. C. Gutierrez, L. Palomera, M. Fuertes, P. Garcia-Sanchez, J. J. Lahuerta, J. de la Rubia, M.-J. Terol, et al.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression
Haematologica, April 1, 2008; 93(4): 560 - 565.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
B. Abrahamsen, I. Andersen, S. S Christensen, J. Skov Madsen, and K. Brixen
Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study
BMJ, April 9, 2005; 330(7495): 818.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Mileshkin, J. J. Biagi, P. Mitchell, C. Underhill, A. Grigg, R. Bell, J. McKendrick, P. Briggs, J. F. Seymour, K. Lillie, et al.
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age
Blood, July 1, 2003; 102(1): 69 - 77.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.